Why Madrigal Pharmaceuticals Stock Slumped on Tuesday [Yahoo! Finance]
Madrigal Pharmaceuticals, Inc. (MDGL)
Last madrigal pharmaceuticals, inc. earnings: 2/26 06:50 am
Check Earnings Report
US:NASDAQ Investor Relations:
madrigalpharma.com
Company Research
Source: Yahoo! Finance
10 stocks we like better than Madrigal Pharmaceuticals › The New Year's Champagne turned flat for Madrigal Pharmaceuticals (NASDAQ: MDGL) on Tuesday. Investors traded out of the commercial-stage biotech following an analyst's recommendation downgrade. This resulted in the stock's price eroding by more than 5% that trading session. The prognosticator behind the downgrade was Wolfe Research's Andy Chen. Well before market open, Chen changed his recommendation on Madrigal to peerperform (hold, in other words) from his previous outperform (buy), at a $572 per share price target His main concern, according to reports, is that Madrigal stock is expensive relative to its performance following a significant bull run on its shares. This was aided greatly by the Food and Drug Administration's (FDA) 2024 approval of the company's Rezdiffra, which, for a time, made the drug the only approved treatment for the liver disorder now known as metabolic dysfunction-associated steatohepatitis (M
Show less
Read more
Impact Snapshot
Event Time:
MDGL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MDGL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MDGL alerts
High impacting Madrigal Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
MDGL
News
- Madrigal Pharmaceuticals (NASDAQ:MDGL) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.MarketBeat
- Madrigal Pharmaceuticals (NASDAQ:MDGL) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..MarketBeat
- Madrigal Pharmaceuticals (NASDAQ:MDGL) had its "buy" rating reaffirmed by analysts at Cowen Inc.MarketBeat
- Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Volatility And Long Term Momentum [Yahoo! Finance]Yahoo! Finance
- Madrigal Pharmaceuticals (MDGL) Is Down 13.4% After Pfizer MASH Deal And Wolfe Downgrade - What's Changed [Yahoo! Finance]Yahoo! Finance
MDGL
Earnings
- 11/4/25 - Miss
MDGL
Sec Filings
- 12/12/25 - Form SCHEDULE
- 12/12/25 - Form SCHEDULE
- MDGL's page on the SEC website